Table 1 |
|
| Clinical and sleep characteristics of multiple system atrophy (MSA) patients | |
| Variables | MSA patients |
| Patients | 25 |
| Male:Female | 10:15 |
| Age at onset (years) | 62.3 ± 1.7 (46–78) |
| Disease duration (months) | 45.9 ± 4.7 (12–96) |
| UMSARS | 48.0 ± 4.0 (17–82) |
| ESS | 6.2 ± 0.9 (0–15) |
| Total sleep time (min) | 322 ± 18 (103–575) |
| Sleep efficiency (%) | 61.9 ± 2.7 (35–95) |
| Stage N1 (%) | 32.1 ± 2.26 (12.6–57.3) |
| Stage N2 (%) | 46.3 ± 3.1 (11.4–69.8) |
| Stage N3 (%) | 5.2 ± 1.4 (0–21.7) |
| Stage REM (%) | 15.6 ± 2.5 (0–44.9) |
| Arousal index (/h) | 43.0 ± 4.1 (0–79.9) |
| AI (/h) | 19.7 ± 4.7 (0–80.8) |
| AHI (/h) | 41.9 ± 6.4 (4.1–117.3) |
| Mean SpO2 (%) | 93.1 ± 3.2 (82–97) |
| PLM index (/h) | 44.2 ± 11.7 (0–166.0) |
| PLM arousal index (/h) | 2.3 ± 0.9 (0–16.2) |
| LED (mg/day) | 352 ± 50 (25–683) |
Values are means ± standard error of the means (SEM; range). MSA, multiple system atrophy; UMSARS, unified multiple system atrophy rating scale; ESS, Epworth sleepiness scale; REM, rapid eye movement; AI, apnea index; AHI, apnea-hypopnea index; SpO2, oxygen saturation; PLM, periodic leg movement; LED, L-dopa-equivalent dose.
Shimohata et al. BMC Neurology 2012 12:130 doi:10.1186/1471-2377-12-130
